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Aim To analyze the pharmacy network (structure and re-
sources) in Bulgaria, Croatia, Serbia, and Slovenia and its re-
lation to public expenditures for medicines.
Methods We performed a cross-sectional study using the 
officially published data for the period 2003-2008 in four 
selected countries. Data sources were relevant national in-
stitutions.
Results  In  2008,  Serbia  had  27.5,  Bulgaria  66.8,  Croatia 
59.5, and Slovenia 71.2 pharmacists per 100 000 inhabit-
ants. There was a significant difference in the number of 
pharmacists  per  100 000  inhabitants  between  all  coun-
tries except between Bulgaria and Slovenia. The number 
of inhabitants per one pharmacy was significantly differ-
ent between all observed countries. The expenditures for 
medicines per capita in 2008 were between €30.34 in Bul-
garia to €137.03 in Slovenia, with a significant difference 
between all countries except between Bulgaria and Serbia. 
The number of pharmacists per 100 000 inhabitants and 
expenditures for medicines per capita were positively cor-
related in all observed countries, except in Bulgaria.
Conclusion There were significant difference in the struc-
ture and availability of the pharmacy service in all selected 
countries. Expenditures for medicines were positively cor-
related with the number of pharmacists in all countries, 
except in Bulgaria. Our findings could be valuable to na-
tional regulatory bodies for the creation of national drug 
policies.
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Regular access to medicines is still a problem for some 
countries in Europe (1). Access to medicines is a complex 
concept, consisting of the dimensions of availability, af-
fordability, and accessibility. Availability, defined as type 
and quantity of health technology needed or provided, 
highly relies on the availability of health care profession-
als and health infrastructure. Affordability is defined as 
the cost to the patient or society imposed by health tech-
nology and accessibility as access to quality health care, 
in terms of the adequate number of health professionals 
and health facilities (2). In case of the pharmaceutical sec-
tor, all of this refers to adequate resources and resource 
allocation. Resources include humans, facilities, and fi-
nancial resources. In plain words, it refers to geographical 
network of pharmacies and pharmacists, as well as opti-
mal medicine financing (2,3). There is a limited number 
of studies investigating pharmacy network and access to 
medicines in Central Eastern European (CEE) countries. 
The study from 2003 reveals a shortage of pharmacists, 
which could have a negative impact on pharmacy servic-
es and their quality (4). The information about the num-
ber of pharmacies is inconsistent. Data on the number 
and ownership type of pharmacies are published for few 
countries, with very scant information for the CEE region 
(4-7).
Development of pharmacy network and access to medi-
cines highly depends on the overall functioning of the 
health care system. Central issue in any health care sys-
tem is the type of financing. CEE countries use mandatory 
social health insurance (often called Bismarckian). Funds 
are collected from the insured persons as percentage of 
their salary. This type of health insurance allows the cov-
erage of almost 100% of the population. Further revenue 
comes in the form of cost sharing for the services covered 
by the benefits package. Cost sharing commonly applies 
to  outpatient  prescription  medicines  and  depends  on 
their life-saving potential, relative therapeutic value, and 
price.
The aim of the study was to analyze the pharmacy net-
work in terms of the number of pharmacies and phar-
macists in four CEE countries – Bulgaria, Croatia, Serbia, 
and Slovenia and to measure the access to medicines 
through  the  public  expenditures  for  medicines,  and 
correlation between these indicators. We tried to eval-
uate if citizens of the selected countries had equal ac-
cess to pharmacy services and reimbursed medicines, 
and compare the results with other European coun-
tries.
MATeriALS AnD MeThoDS
Design and methodology
We conducted a cross-sectional study in Bulgaria, Croatia, 
Serbia, and Slovenia. These countries were selected be-
cause their pharmaceutical sector was a centralized mar-
ket until 1990 after which changes in its structure and fi-
nancing occurred. All the selected countries have just one 
public health insurance fund, similar socio-economic de-
velopment, and similar public health expenditures (as per-
cent of gross domestic product).
Pharmacy network and access to medicines was evaluated 
using the following indicators: number and type of phar-
macies, number of inhabitants per one pharmacy, num-
ber of pharmacists, public expenditures for medicines, and 
public expenditures for medicines per capita. The number 
and distribution of pharmacists and pharmacies were fac-
tors important for availability, while organization (types of 
facilities) and financing (cost sharing and co-payment ar-
rangements) were important for accessibility, affordability, 
and quality of health care system (3,8).
Data sources
We used the officially published data for the period 2003-
2008. Population data for all 4 countries were obtained 
from the database of national institutes for statistics (9-12). 
All community pharmacies were included in the analysis 
and hospital pharmacies were excluded since they are not 
directly available to out-patients (3). In Bulgaria, the num-
ber of publicly owned and private pharmacies, number of 
pharmacists, and public expenditures for medicines were 
obtained from the Ministry of Health database (13). In Cro-
atia, the number of pharmacists and the number and type 
of pharmacies were obtained from the Croatian Nation-
al Institute of Public Health (14). In Serbia, the number of 
pharmacists and number of private pharmacies were ob-
tained from the Statistical Office of the Republic of Serbia 
(11) and the number of public pharmacies was obtained 
by  a  telephone  interview  with  each  of  the  29  regional 
pharmacy institutions. In Slovenia, the number and type of 
pharmacies was obtained from the database of the Slove-
nian Chamber of Pharmacy (15) and the number of phar-
macists was obtained from Slovenian Institute for Public 
Health (16).
Expenditures for medicines data were obtained from the 
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tute for Health Insurance (18), the Health Insurance Insti-
tute of Slovenia (19), and the Ministry of Health of Bulgaria 
regarding the payments for life saving medicines and from 
the National Health Insurance Fund for all other reimbursed 
medicines. All expenditures are presented in Euro, using 
the following average exchange rates: Bulgaria €1 = BGN 
1.95; Croatia €1 = HRK 7.39, and Serbia €1 = RSD 79.79).
Statistical analysis
Mean values of the number of pharmacists per 100 000 in-
habitants and the number of inhabitants per one commu-
nity pharmacy were compared between the four countries 
with one-way ANOVA. Testing for significant differences 
between groups was performed with Tukey HSD post-hoc 
test. The effects of the number of pharmacists and number 
of pharmacies per 100 000 inhabitants on public expendi-
tures per capita were tested by linear regression analysis. A 
two-tailed P ≤ 0.05 was considered significant. All calcula-
tions were performed using STATGRAPHIC Plus, version 4.2 
software (Statpoint Technologies Inc., Warrenton, VA, USA).
reSuLTS
All countries had two or more times more pharmacists per 
100 000 inhabitants than Serbia. In 2008, Serbia had only 
27.5 pharmacists per 100 000 inhabitants, while Bulgaria, 
Croatia, and Slovenia had 66.8, 59.5, and 71.2 pharmacists, 
respectively (Figure 1). A significant difference in the num-
ber of pharmacists per 100 000 inhabitants was observed 
between all countries (F = 122.89; P < 0.001 ANOVA with 
Tukey post-hoc test), except between Bulgaria and Slo-
venia. The greatest number of pharmacists per pharmacy 
was observed in Slovenia (5.29 pharmacists per pharmacy 
in 2008), while Serbia in 2008 had just 0.67 pharmacist per 
pharmacy, although one pharmacist per pharmacy is the 
minimum legal requirement (Figure 2).
In Bulgaria, all community pharmacies (n = 4557 in 2008) 
were  privately  owned  (either  independent  or  part  of 
a  pharmacy  chain).  In  Croatia,  the  number  of  privately 
owned pharmacies gradually grew from 321 in 2003 to 445 
in 2008, reaching a total of 55% of all pharmacies. In Serbia, 
the majority of pharmacies (around 80% of 2995 in 2008) 
were privately owned, but only publicly owned pharma-
cies (590 in 2008) were allowed to dispense reimbursed 
medicines according to the contract with Republic Insti-
tute for Health Insurance. In Slovenia, the number of phar-
macies remained almost constant during the observed pe-
riod and the majority of them (approximately 70%) were 
publicly owned. The greatest number of inhabitants per 
pharmacy was in Slovenia, with approximately 7000 in-
habitants (Table 1). The number of inhabitants per one 
pharmacy was significantly different between all countries 
(F = 210.66; P < 0.001). Public expenditures for medicines 
per capita in 2008-year ranged between €30.34 in Bulgaria 
to €137.03 in Slovenia (Table 2). There was a significant dif-
ference in public expenditures for medicines between all 
countries except between Bulgaria and Serbia (F = 233.64; 
P < 0.001) (Figure 3).
Correlation  analysis  between  the  number  of  pharma-
cist per 100 000 inhabitants and public expenditures for 
medicines  per  capita  showed  a  positive  correlation  for 
all  observed  countries,  except  Bulgaria. The  number  of 
pharmacists explained more than 93% of the variation in 
FiGure 1. number of pharmacists per 100 000 inhabitants in Bulgaria, 
Croatia, Serbia, and Slovenia in the period 2003-2008.
FiGure 2. number of pharmacists per one pharmacy in Bulgaria, Croatia, 
Serbia, and Slovenia in the period 2003-2008.HEALTH CARE 56 Croat Med J. 2012;53:53-9
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expenditures in Croatia (b = 4.47, r = 0.968, P = 0.001); 71% 
in Serbia (b = 5.82, r = 0.847, P = 0.033), and 70% in Slovenia 
(b = 1.24, r = 0.818, P = 0.046). When we compared pharma-
cies instead of pharmacists, univariate regression analysis 
showed a significant correlation between the number of 
pharmacies and expenditures for medicines only in Slove-
nia (b = 16.67, r = 0.914, P = 0.011).
DiSCuSSion
Our study showed that all investigated countries had dif-
ferent number of responsible pharmacists and that Serbia 
had significantly fewer pharmacists than Bulgaria, Croatia, 
or Slovenia. Serbia had almost three times fewer phar-
macists than Bulgaria or Slovenia and two times fewer 
than Croatia. We used the number of inhabitants per one 
pharmacy as the indicator of accessibility to medicines and 
other pharmacy services (2). The smallest number of inhabit-
ants per pharmacy was observed in Bulgaria, while Slovenia 
had more than 4 times higher value. Due to high number of 
inhabitants per pharmacy, Slovenia seems to have the low-
est accessibility to pharmacy services, but on the other hand 
it has the highest number of pharmacists per pharmacy. 
Also, Croatia had a large difference in the number of inhab-
itants per pharmacy between 2007 and 2008, which could 
be explained by huge decline in the number of publicly 
owned pharmacies in 2008 (almost by 50%). The study also 
found big differences in public expenditures for medicines 
between the countries and a positive correlation between 
these expenditures and the number of pharmacists.
In Europe (27 EU member states, Croatia, FYR Macedonia, 
Norway, Switzerland, and Turkey) in 2006, the average num-
ber of responsible pharmacists per community pharmacy 
was 2.4. At the same time, there were 176 053 community 
pharmacies, which corresponds to an average of 3300 in-
habitants per pharmacy (20). A possible reason for the small 
number of pharmacists in Serbia could be a low socioeco-
nomic status and migration of health workers. Migration of 
health workers from the new to old EU members has been 
previously noticed (21,22), and further migration could be 
expected from Croatia and Serbia after their accession to 
the EU. In Europe, the average number of pharmacists per 
100 000 in 2006 was 52.28, while in the EU it was 71.43 (23), 
ranging from 17 per 100 000 in the Netherlands to 89 per 
100 000 in Ireland (8). The smallest number of pharmacists 
per 100 000 in the world (only 1) is observed in some coun-
tries of Africa and the Middle-East (24,25).
Pharmacists play an important role in the prevention and 
treatment  of  diseases.  In  the  29-professions  survey  in 
Australia, they were placed among the most ethical and 
honest professions (26). Often, they represent the only 
point of contact with the health care system. Even with 
the adequate number of pharmacists, the average time 
for advice and counseling in pharmacy is about 2 minutes 
(27), which means that in countries with a low number of 
pharmacists (like Serbia) the quality of pharmacy servic-
es, especially pharmaceutical care, is questionable. Serbia 
had just one pharmacist per 4000 inhabitants during the 
observed period, while Slovenia had one pharmacist per 
1300 inhabitants.
There were great differences in the number of inhabitants 
per community pharmacy between countries. The reasons 
TABLe 1. number of inhabitants per pharmacy in Bulgaria, 
Croatia, Serbia, and Slovenia (year 2003-2008)
2003 2004 2005 2006 2007 2008
Bulgaria 1858 1793 1816 1658 1659 1669
Croatia 4185 4118 4083 4022 3102 5459
Serbia 2584 2442 2444 2753 2501 2454
Slovenia 7769 7479 7384 7023 7086 6984
TABLe 2. Public expenditures for medicine per capita in Bul-
garia, Croatia, Serbia, and Slovenia in year 2008
Country Public expenditures per capita (€)
Bulgaria   30.34*
Croatia 105.80*
Serbia   34.16*
Slovenia 137.03
*Conversion rates: Bulgaria €1 = BGn 1.95; Croatia €1 = hrK 7.39; and 
Serbia €1 = rSD 79.79.
Figure 3. Public expenditures for medicine per capita for Bulgaria, Croa-
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for these differences may be regulatory – pharmacies in 
Slovenia is are owned exclusively by licensed pharmacists, 
which is not the case in Bulgaria (28,29). They may also 
be geographical – in Slovenia the distance between two 
pharmacies must be at least 400 m, with the number of 
inhabitants covered by a pharmacy ranging from 5000 to 
7000 (30), while the Bulgarian pharmacy network is over-
developed so there are often many pharmacies in an area 
of only a few hundred square meters (31). This could also 
be related to pharmacy infrastructure (possibility the ex-
istence of a few, large pharmacies in Slovenia). Denmark 
has the greatest number of inhabitants per pharmacy in 
the EU (6) and Greece has the smallest (32). EU average in 
2006 was about 3300 inhabitants per pharmacy, with 2.4 
responsible pharmacists per pharmacy (20).
The  number  of  pharmacies  is  associated  with  multiple 
market factors (33). In Serbia, reimbursable medicines are 
dispensed only by publicly owned pharmacies, since only 
they have contracts with the Serbian Health Insurance In-
stitute. For years, private pharmacies are trying to become 
integral part of this network, but with little effect. If the 
number of inhabitants per pharmacy is calculated solely 
on the basis of publicly owned pharmacies, it would be 
almost 13 000. Since the number of pharmacists per phar-
macy in Serbia is small, accessibility of pharmacy services 
and medicines could be jeopardized. A possible explana-
tion for the small number may lay in the fact that although 
pharmacists’ licensing became obligatory in 2008 (34), the 
inspections by Ministry of Health were rare due to a small 
number of inspectors.
The differences in public expenditures for medicines per 
capita in the observed countries may be influenced by dif-
ferences in legislation, mainly size of contribution to the 
national insurance funds (15% in Croatia, 13.45% Slovenia, 
12.3% in Serbia, and 6% in Bulgaria) (35-37); pharmaceuti-
cal regulatory aspect (cost containment measures for pric-
ing and reimbursement of medicines, different wholesale 
and retail margins, and difference in value added tax for 
medicines), and out-of-pocket spending (in Bulgaria 44.8% 
of total health care expenditures was allocated on out-of-
pocket spending in 2004 and in Slovenia only 9.7%) (36). 
Regulatory policies in CEE countries are trying to reduce 
costs through restrictions in prescribing high volume or 
expensive medicines (38-40).
Expenditures for medicines are one of the fastest grow-
ing  components  of  the  total  health  expenditures  and 
are ranked third after the hospital and ambulatory health 
care expenditures (41). The increase is attributed to great-
er demand, aging population, and innovative, expensive 
medicines. There is a lack of data on average per capita ex-
penditures for medicines in Europe (7); Organization for 
Economic Co-operation and Development (OECD) coun-
tries had average expenditures of USD 446 in 2006, mean-
ing  that  all  analyzed  CEE  countries  were  far  below  the 
OECD average. A previous study confirmed that other CEE, 
post-2004 EU member countries had lower expenditures 
for medicines per capita, eg, Poland GBP 66, than pre-2004 
EU countries (42).
Interestingly, only Bulgaria had a weak negative association 
between the number of pharmacists and public expendi-
tures per capita. In Bulgaria, the number of pharmacists de-
clined in 2008 after all pharmacists practicing their profes-
sion had been required to register (43). Hence, pharmacists 
in pharmaceutical companies, representative offices, and 
similar did not register, which could explain the weak neg-
ative correlation and the small correlation coefficient.
Our study dealt only with the pharmacy sector, which led 
to certain limitations. First, it did not include physicians, al-
though several studies found that physicians were one of 
key elements that affected the utilization of reimbursed 
medicines (44,45). Second, we used the database on the 
utilization of prescription medicines rather than on all au-
thorized medicines dispensed through pharmacies, and 
this might affect the overall results of the study. In Serbia, 
there is a considerable difference in the data on utilization 
of medicines obtained from the Institute for Health Insur-
ance, which gathers data on prescription medicines, and 
those obtained from the Medicines and Medical Devices 
Agency,  which  gathers  all  medicine  consumption  data. 
The Agency gathers data on annual consumption of their 
authorized  medicines  by  pharmaceutical  companies  or 
representative offices, which reflects only the volume of 
produced or imported medicines rather than that of medi-
cines actually used by patients (46-49). Also, utilization da-
tabases of all market-approved medicines are not available 
in every studied country. Finally, we did not explore the 
availability of particular key medicines (for example, statins, 
proton pump inhibitors, or biotechnology medicines).
In conclusion, there are great differences in the develop-
ment of pharmacy sector in the selected countries. The 
availability of pharmacy service seems to be sufficient in 
Croatia and Slovenia, but could be insufficient in Serbia 
due to small number of pharmacists. Access to medi-
cines is increasing in all CEE countries; however, it is HEALTH CARE 58 Croat Med J. 2012;53:53-9
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still lower than in more economically developed EU coun-
tries. Our findings could be valuable to national regulatory 
bodies and could be used in the creation of national drug 
policies. It would be beneficial to further evaluate the avail-
ability of selected medicines (eg, brand medicines and ge-
nerics).
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